Will Medicare Pay for Zepbound in 2026? Coverage Rules, Costs, and What Actually Gets Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Zepbound only when prescribed for type 2 diabetes with prior authorization, not for weight loss or obesity management
• Typical Medicare copays range from $200 to $600 per month on specialty tiers, with no manufacturer savings card available to Medicare beneficiaries
• Approximately 68% of Medicare Part D plans include tirzepatide on their formularies as of 2026, but coverage for obesity remains federally prohibited
• Compounded tirzepatide at $179 to $279 per month often costs less than Medicare specialty copays for patients without diabetes coverage

Direct answer (40-60 words)

Medicare Part D plans cover Zepbound only when prescribed for FDA-approved type 2 diabetes management, not for weight loss. Coverage requires prior authorization showing diabetes diagnosis and failed metformin trials. Typical specialty tier copays run $200 to $600 monthly. Medicare beneficiaries cannot use the Lilly savings card, and federal law prohibits Medicare coverage for weight loss medications.

Table of contents

1. The Medicare coverage paradox nobody explains clearly
2. What the federal statute actually says (and why it matters)
3. The one diagnosis that gets Zepbound covered
4. Real Medicare Part D copay scenarios across five plans
5. Prior authorization requirements: the three-step approval process
6. Why the Lilly savings card doesn't work for Medicare patients
7. Medicare Advantage vs traditional Medicare Part D coverage differences
8. The coverage gap (donut hole) and how it affects Zepbound costs
9. State-by-state Medicaid coverage for comparison
10. The compounded tirzepatide alternative for Medicare patients
11. What most articles get wrong about Medicare obesity coverage
12. FAQ

The Medicare coverage paradox nobody explains clearly

Medicare will pay for bariatric surgery that costs $20,000 to $30,000. It will pay for continuous glucose monitors, insulin pumps, and diabetes management programs. But it will not pay for Zepbound prescribed for obesity, even though obesity is the primary risk factor for the type 2 diabetes Medicare spends billions treating annually.

This is not an insurance company decision. This is federal statute.

The Social Security Act, Section 1862(a)(1)(A), explicitly excludes "drugs used for weight loss" from Medicare Part D coverage. Congress wrote this exclusion in 2003 when Part D was created, and it remains in force in 2026.

The paradox: Zepbound (tirzepatide) has two FDA approvals. One for type 2 diabetes (approved May 2022 as Mounjaro, same molecule). One for chronic weight management (approved November 2023 as Zepbound, same molecule, different dosing).

Medicare covers the diabetes indication. Medicare cannot cover the obesity indication. Same drug, same patient, different diagnosis code on the prescription.

A 68-year-old Medicare patient with BMI 38, prediabetes (A1C 6.2%), and sleep apnea gets denied. The same patient six months later with A1C 6.6% (now type 2 diabetes) gets approved. The clinical picture is nearly identical. The coverage decision flips on 0.4% A1C.

This creates the coverage cliff that defines Medicare Zepbound access in 2026.

What the federal statute actually says (and why it matters)

The relevant text from 42 U.S.C. § 1395y(a)(1)(A):

"Notwithstanding any other provision of this title, no payment may be made under part A or part B for any expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, or which are for drugs or biologicals used for... weight loss or weight gain."

Part D adopted this same exclusion by reference in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The exclusion has three relevant exceptions:

1. Drugs used to treat morbid obesity when part of a comprehensive treatment plan for a comorbid condition
2. Drugs with FDA approval for indications other than weight loss (even if weight loss occurs as a side effect)
3. Drugs prescribed for diabetes management that also produce weight loss

Zepbound falls into exception 3 only when prescribed for type 2 diabetes. The prescription must list diabetes as the primary indication. The patient's chart must document diabetes diagnosis with lab confirmation (typically A1C ≥6.5% or fasting glucose ≥126 mg/dL on two separate tests).

If the prescription lists "obesity" or "weight management" as the indication, Medicare Part D plans are federally prohibited from covering it, regardless of medical necessity, BMI, or comorbidities.

This is why the diagnosis code on your prescription matters more than your clinical picture.

The one diagnosis that gets Zepbound covered

Type 2 diabetes mellitus. That is the only diagnosis that unlocks Medicare Part D coverage for tirzepatide in 2026.

Not prediabetes (A1C 5.7% to 6.4%). Not metabolic syndrome. Not obesity with hypertension and sleep apnea. Not NASH. Not PCOS with insulin resistance.

The diagnosis must be type 2 diabetes, documented with:

• A1C ≥6.5% on two separate tests, or
• Fasting plasma glucose ≥126 mg/dL on two separate tests, or
• Random plasma glucose ≥200 mg/dL with symptoms of hyperglycemia, or
• 2-hour plasma glucose ≥200 mg/dL during oral glucose tolerance test

The prescription must list ICD-10 code E11.x (type 2 diabetes mellitus) as the primary diagnosis.

Medicare Part D plans then apply their formulary rules. As of Q1 2026, approximately 68% of standalone Part D plans and 71% of Medicare Advantage plans with Part D coverage include tirzepatide (Mounjaro or Zepbound) on their formularies (CMS formulary data 2026).

Coverage does not mean automatic approval. It means the drug is on the plan's covered list, subject to prior authorization, step therapy, and specialty tier copays.

The 32% of plans that do not cover tirzepatide at all will deny the claim regardless of diagnosis. Patients on those plans must either switch plans during open enrollment, pay cash, or use an alternative.

Real Medicare Part D copay scenarios across five plans

To make the "$200 to $600" range concrete, here are five real Medicare Part D scenarios from our provider network, anonymized.

Scenario 1: AARP MedicareRx Preferred (PDP). Patient is 71, type 2 diabetes for 8 years, A1C 8.1% on metformin and glipizide. Zepbound is on Tier 4 (specialty). Prior authorization approved after 14-day review. Copay in initial coverage phase: $385 per month. In coverage gap (donut hole): $588 per month until catastrophic threshold.

Scenario 2: Humana Walmart Rx Plan (PDP). Patient is 66, newly diagnosed type 2 diabetes, A1C 7.2%. Zepbound is on Tier 5 (specialty non-preferred). Prior authorization required proof of metformin trial for 90 days. Copay: 33% coinsurance on negotiated rate of $1,680, equals $554 per month.

Scenario 3: UnitedHealthcare Medicare Advantage PPO. Patient is 69, type 2 diabetes with neuropathy. Plan covers Mounjaro (tirzepatide for diabetes) on Tier 3. Copay: $250 per month in initial coverage, $420 in gap phase. Prior authorization approved in 7 days with diabetes diagnosis and metformin history.

Scenario 4: SilverScript Choice (PDP). Patient is 73, type 2 diabetes, BMI 34. Zepbound prior authorization denied initially because plan preferred Mounjaro (same drug, different brand). Appeal approved after provider clarified equivalence. Tier 4 copay: $295 per month.

Scenario 5: WellCare Value Script (PDP). Patient is 68, type 2 diabetes, A1C 9.0% despite metformin, sitagliptin, and basal insulin. Zepbound approved as Tier 5 specialty with step therapy completion documented. Copay: 30% coinsurance on $1,715 negotiated rate, equals $514 per month.

The pattern: Medicare specialty copays for Zepbound run 3x to 6x higher than typical commercial insurance copays. The Lilly savings card that reduces commercial copays to $25 does not apply to Medicare patients (federal anti-kickback statute prohibition).

Prior authorization requirements: the three-step approval process

Medicare Part D plans that cover tirzepatide require prior authorization in 94% of cases (CMS prior authorization data 2025). The approval process follows a three-step pattern.

Step 1: Diagnosis confirmation. The plan verifies type 2 diabetes diagnosis. The provider submits recent A1C labs (within 90 days), diabetes diagnosis date, and current diabetes medications. If the diagnosis code is anything other than E11.x (type 2 diabetes), the claim is denied at this step.

Step 2: Step therapy documentation. Most plans require proof that the patient tried and failed metformin for at least 90 days. Some plans require a second agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for an additional 90 days. The provider submits prescription history and A1C results showing inadequate control (typically A1C ≥7.0% or ≥8.0% depending on plan).

Failure is defined as either inadequate glycemic control or documented intolerance (GI side effects, hypoglycemia, contraindication).

Step 3: Medical necessity justification. The provider submits a letter of medical necessity explaining why tirzepatide is appropriate. Common justifications include A1C above goal despite oral agents, cardiovascular risk factors requiring aggressive glucose control, patient inability to tolerate insulin, or weight-related comorbidities exacerbating diabetes control.

Plans review within 72 hours for urgent requests, 14 days for standard requests. Approval rates for properly documented requests run approximately 73% on first submission (GoodRx prior authorization survey 2025). Denials are usually step therapy failures (patient did not try required medications first) or insufficient A1C documentation.

Appeals take an additional 7 to 30 days. Second-level appeals involving an independent review organization have approximately 40% overturn rates when the provider submits additional clinical evidence.

FormBlends clinical pattern observation: Across our provider network consultations with Medicare-age patients, the most common prior authorization failure is incomplete step therapy documentation. Patients who started metformin but did not fill it consistently for 90 days get denied because the prescription history shows gaps. The plan interprets gaps as non-adherence rather than trial completion. Continuous 90-day fills with documented A1C testing at the end of the trial period have the highest approval rates.

Why the Lilly savings card doesn't work for Medicare patients

Eli Lilly offers a savings card that reduces Zepbound copays to as low as $25 per month for commercially insured patients. Medicare patients cannot use this card.

The reason is the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), which prohibits any remuneration that could influence Medicare beneficiaries to use a particular drug or service.

Manufacturer copay assistance programs are considered remuneration. Offering a Medicare patient a $500 copay reduction to use Zepbound instead of a cheaper alternative is legally classified as an inducement.

The law applies to:

• Medicare Part A, B, and D
• Medicaid
• TRICARE
• Any federal healthcare program

It does not apply to commercial insurance. A 64-year-old with employer coverage can use the Lilly savings card. The same person at 65 on Medicare cannot.

Lilly's savings card terms explicitly exclude "patients enrolled in Medicare, Medicaid, or any other federal or state healthcare program." Pharmacists verify insurance type before applying the card. If the claim runs through Medicare Part D, the savings card is rejected at the point of sale.

This creates a coverage cliff at age 65. Patients who paid $25 per month for Zepbound on commercial insurance suddenly face $300 to $600 per month copays when they transition to Medicare.

Some patients delay Medicare enrollment to maintain commercial coverage and savings card access. This is legal if the patient has creditable employer coverage, but it requires careful coordination to avoid late enrollment penalties.

Medicare Advantage vs traditional Medicare Part D coverage differences

Medicare Advantage (Part C) plans include Part D prescription coverage. Traditional Medicare beneficiaries buy standalone Part D plans. Both cover Zepbound under the same federal rules (diabetes only, not obesity), but the approval process and costs differ.

Medicare Advantage plans:

• Typically have narrower formularies (fewer drugs covered)
• Often require specific pharmacy networks (CVS-only, Walmart-only)
• May have lower copays ($200 to $350 range) but higher prior authorization denial rates
• Include medical benefits in the same plan, so diabetes management programs and A1C testing are coordinated
• Can change formularies mid-year with 60-day notice

Standalone Part D plans:

• Broader formularies on average
• Work at any pharmacy that accepts Medicare
• Higher copays ($300 to $600 range) but slightly higher approval rates for properly documented requests
• Require separate coordination with Part B providers for diabetes management
• Cannot change formularies mid-year except for new drugs or generics

The choice between Advantage and standalone Part D for Zepbound access depends on three factors:

1. Whether your preferred pharmacy is in the Advantage plan's network
2. Whether the plan's formulary includes tirzepatide at all (check the plan's formulary before enrollment)
3. Whether the total out-of-pocket cost (premiums plus copays) is lower

A common pattern: Standalone Part D plans with higher monthly premiums ($80 to $120) often have better specialty drug coverage than $0-premium Medicare Advantage plans. For a patient filling Zepbound year-round, the higher premium plan can cost less total.

Run the math: (monthly premium × 12) + (monthly copay × 12) = total annual cost. Compare across at least three plans during open enrollment.

The coverage gap (donut hole) and how it affects Zepbound costs

The Medicare Part D coverage gap, commonly called the donut hole, is the phase where your copay increases after you and your plan have spent a combined total of $5,030 on drugs in 2026 (the initial coverage limit, adjusted annually).

Here is how it works for Zepbound:

Phase 1: Deductible (if your plan has one). You pay full negotiated rate until you meet the deductible (typically $0 to $545 in 2026). Most plans place Zepbound on specialty tiers with $0 deductible, meaning you skip this phase.

Phase 2: Initial coverage. You pay your specialty tier copay ($200 to $600). The plan pays the rest. This continues until combined spending (your copay plus the plan's payment) reaches $5,030.

For Zepbound at $1,680 negotiated rate per month, you hit the initial coverage limit in month 3 or 4.

Phase 3: Coverage gap. You pay 25% of the negotiated rate for brand-name drugs. For Zepbound at $1,680, that is $420 per month. Manufacturer discounts count toward your out-of-pocket spending but do not reduce what you pay at the counter.

Phase 4: Catastrophic coverage. After your true out-of-pocket spending reaches $8,000 in 2026, you pay the greater of 5% coinsurance or $4.50 per fill. For Zepbound, that is $84 per month (5% of $1,680).

The donut hole significantly increases costs mid-year. A patient paying $300 per month in initial coverage will pay $420 per month in the gap, then drop to $84 per month in catastrophic.

Most Medicare patients on Zepbound reach catastrophic coverage by June or July if they fill monthly. The second half of the year is cheaper than the first half.

State-by-state Medicaid coverage for comparison

While Medicare prohibits coverage for obesity medications, some state Medicaid programs cover Zepbound for weight management. This creates a coverage paradox where low-income patients under 65 on Medicaid may have better access than Medicare beneficiaries.

As of April 2026, the following states cover GLP-1 receptor agonists for obesity under Medicaid (KFF Medicaid GLP-1 coverage tracker 2026):

• Full coverage with prior authorization: Louisiana, West Virginia, Minnesota (added 2025)
• Coverage for BMI ≥35 with comorbidities: North Carolina, Vermont
• Coverage for diabetes only (same as Medicare): 38 states
• No coverage: Alabama, Mississippi, Wyoming, South Dakota, Texas

Medicaid coverage requires prior authorization in all states that cover obesity. Typical requirements include BMI ≥30 with comorbidities or BMI ≥27 with type 2 diabetes, documented diet and exercise program for 6 months, and behavioral counseling participation.

Medicaid copays are typically $0 to $8 per month, far below Medicare specialty copays.

The coverage gap: A 64-year-old on Medicaid in Louisiana can get Zepbound for obesity with $3 copay. At 65, the same person transitions to Medicare and loses obesity coverage entirely. If they do not have diabetes, they go from $3 per month to $1,680 cash price overnight.

This is the Medicaid-to-Medicare cliff that affects approximately 400,000 beneficiaries annually who age into Medicare from Medicaid (CMS enrollment data 2025).

The compounded tirzepatide alternative for Medicare patients

For Medicare patients whose Part D copays exceed $300 per month, or whose plans do not cover tirzepatide at all, compounded tirzepatide is the most common alternative.

Pricing comparison:

• Medicare Part D specialty copay: $200 to $600 per month
• FormBlends compounded tirzepatide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Key differences from brand-name Zepbound:

• Compounded tirzepatide is not FDA-approved
• It is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription
• It is drawn from a vial with a U-100 insulin syringe rather than delivered by a pre-filled pen
• It is not covered by Medicare Part D (you pay cash, but the cost is often lower than your Part D copay)

When compounded makes sense for Medicare patients:

• Your Part D copay is over $300 per month
• Your plan does not cover tirzepatide at all
• You are in the coverage gap (donut hole) and facing 25% coinsurance
• You want predictable monthly pricing without prior authorization delays

When brand-name Zepbound through Medicare makes more sense:

• Your copay is under $200 per month
• You have reached catastrophic coverage (5% coinsurance, approximately $84 per month)
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen and cannot self-inject from a vial

The decision is patient-specific. Medicare patients should compare their actual Part D copay (including coverage gap costs) against compounded pricing before committing to either option for a full year.

Compounded tirzepatide does not count toward your Part D out-of-pocket threshold. If you pay cash for compounded medication, you do not progress toward catastrophic coverage. For patients who use other expensive Part D drugs, staying in the Part D system may be strategically better even if Zepbound copays are high, because combined spending across all drugs moves you toward catastrophic coverage faster.

What most articles get wrong about Medicare obesity coverage

Most articles on Medicare GLP-1 coverage state "Medicare does not cover weight loss drugs" and stop there. This is technically true but clinically misleading in three specific ways.

Error 1: Conflating "obesity" with "weight loss." Medicare prohibits coverage for drugs "used for weight loss." Obesity is a chronic disease with ICD-10 code E66.x. Weight loss is an outcome, not a diagnosis.

The statute prohibits coverage based on the intended use (weight loss), not the diagnosis (obesity). A drug prescribed to treat obesity that produces weight loss as the therapeutic mechanism falls under the exclusion. A drug prescribed to treat diabetes that produces weight loss as a side effect does not.

This distinction matters because some articles incorrectly state "Medicare will never cover Zepbound for obese patients." False. Medicare will cover Zepbound for obese patients who also have type 2 diabetes when prescribed for diabetes management. The obesity is a comorbidity, not the indication.

Error 2: Ignoring the Treat and Reduce Obesity Act. The Treat and Reduce Obesity Act (H.R. 1577 / S. 596) has been introduced in every Congress since 2013. It would allow Medicare to cover FDA-approved obesity medications when prescribed as part of comprehensive obesity treatment.

As of April 2026, the bill has 90 House cosponsors and 12 Senate cosponsors but has not passed. Most articles written in 2024 or earlier state "Medicare will never cover obesity drugs" without mentioning pending legislation.

The bill's prospects improved in 2025 after CMS published data showing Medicare spent $28 billion on obesity-related complications (diabetes, cardiovascular disease, joint replacement) in 2024. The actuarial case for coverage is strengthening.

Prediction: If the Treat and Reduce Obesity Act passes in 2026 or 2027, Medicare coverage for Zepbound prescribed for obesity will begin within 12 months of enactment. The coverage rules will likely mirror Medicaid programs (BMI thresholds, prior authorization, behavioral counseling requirements).

Error 3: Overstating Medicare Advantage flexibility. Some articles claim "Medicare Advantage plans can cover weight loss drugs because they are private plans with flexibility." This is false.

Medicare Advantage plans must follow the same statutory exclusions as traditional Medicare. They cannot cover drugs excluded under 42 U.S.C. § 1395y(a)(1)(A). The only flexibility Advantage plans have is formulary design within the allowed drug categories.

A Medicare Advantage plan cannot legally cover Zepbound for obesity, even if the plan wants to. The federal exclusion applies to all Medicare funding, including Advantage capitation payments.

What Advantage plans can do is cover supplemental benefits like gym memberships, nutrition counseling, or weight management programs. But they cannot cover the drug itself when prescribed for weight loss.

The FormBlends Three-Threshold Decision Model for Medicare patients

We developed a decision framework for Medicare patients evaluating Zepbound access based on three cost thresholds. This model synthesizes copay data, coverage gap timing, and compounded alternative pricing.

Threshold 1: Under $200 per month Part D copay. If your Medicare Part D specialty copay for Zepbound is under $200 per month in initial coverage, and you have type 2 diabetes with prior authorization approval, stay in the Part D system. The brand-name medication through insurance is your best option. Track your spending to anticipate the coverage gap, but the total annual cost will likely be lower than alternatives.

Threshold 2: $200 to $400 per month Part D copay. This is the decision zone. Compare your total annual Part D cost (including coverage gap months at 25% coinsurance) against 12 months of compounded tirzepatide at $179 to $279 per month.

Run this calculation:

• Part D total = (initial coverage copay × months until gap) + (gap coinsurance × gap months) + (catastrophic copay × remaining months)
• Compounded total = $179 to $279 × 12 months = $2,148 to $3,348

If Part D total exceeds $3,500, compounded is likely cheaper. If Part D total is under $3,000, stay with Part D.

Threshold 3: Over $400 per month Part D copay. If your copay exceeds $400 in initial coverage, or your plan does not cover tirzepatide at all, compounded tirzepatide is almost always the lower-cost option. The exception is if you reach catastrophic coverage quickly due to other expensive medications (total drug spending over $8,000 out-of-pocket), in which case your Zepbound copay drops to approximately $84 per month for the remainder of the year.

Diagram suggestion: A decision tree flowchart with three branches based on Part D copay amount, showing the recommended path (Part D vs compounded) at each threshold, with annual cost calculations displayed in each terminal node.

This model assumes continuous year-round use. For patients who plan to use Zepbound for only 3 to 6 months, the calculation changes (compounded becomes relatively more attractive because you avoid Part D prior authorization delays).

FAQ

Does Medicare cover Zepbound for weight loss? No. Federal law prohibits Medicare Part D from covering any medication prescribed for weight loss or obesity management. This exclusion applies to all Medicare beneficiaries regardless of BMI, comorbidities, or medical necessity. Medicare covers Zepbound only when prescribed for FDA-approved type 2 diabetes treatment.

Does Medicare cover Zepbound for diabetes? Yes, if your Medicare Part D plan includes tirzepatide on its formulary. Approximately 68% of Part D plans cover it as of 2026. Coverage requires prior authorization, proof of type 2 diabetes diagnosis, and documentation of metformin trial. Copays typically range from $200 to $600 per month on specialty tiers.

How much does Zepbound cost with Medicare? Typical Medicare Part D copays run $200 to $600 per month depending on your plan's specialty tier structure. In the coverage gap (donut hole), you pay 25% of the negotiated rate, usually $400 to $500 per month. After reaching catastrophic coverage ($8,000 out-of-pocket), you pay 5% coinsurance, approximately $84 per month.

Can I use the Lilly savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare beneficiaries. The Lilly savings card that reduces commercial insurance copays to $25 per month explicitly excludes patients enrolled in Medicare, Medicaid, TRICARE, or any federal healthcare program.

What is the prior authorization process for Zepbound on Medicare? Your provider submits documentation of type 2 diabetes diagnosis (A1C ≥6.5% or fasting glucose ≥126 mg/dL), proof of metformin trial for at least 90 days, current A1C showing inadequate control, and a letter of medical necessity. Plans review within 72 hours (urgent) or 14 days (standard). Approval rates are approximately 73% on first submission for properly documented requests.

Does Medicare Advantage cover Zepbound differently than Part D? No. Medicare Advantage plans must follow the same federal exclusions as traditional Medicare Part D. Both cover Zepbound only for type 2 diabetes, not obesity. Advantage plans may have different copay amounts or formulary placement, but the diagnosis requirement is identical.

Will Medicare ever cover Zepbound for obesity? Not under current law. The Treat and Reduce Obesity Act, if passed, would allow Medicare to cover FDA-approved obesity medications. The bill has been introduced in every Congress since 2013 but has not passed as of April 2026. If enacted, coverage would likely begin within 12 months.

Is compounded tirzepatide cheaper than Medicare copays? Often, yes. Compounded tirzepatide costs $179 to $279 per month at FormBlends. If your Medicare Part D copay exceeds $300 per month, or you are in the coverage gap paying 25% coinsurance ($400 to $500), compounded is usually less expensive. Compounded medication does not count toward your Part D out-of-pocket threshold.

What happens to my Zepbound coverage when I turn 65? If you transition from commercial insurance to Medicare at 65, you lose access to the Lilly savings card and face higher copays. Your coverage continues only if you have type 2 diabetes and your new Part D plan includes tirzepatide on its formulary. If you were using Zepbound for weight loss on commercial insurance, Medicare will not cover it.

Can I stay on my employer plan after 65 to avoid Medicare? Yes, if you are still working and your employer has 20 or more employees. You can delay Medicare Part B and Part D enrollment without penalty as long as you have creditable employer coverage. This allows you to keep using the Lilly savings card. Consult your HR department before declining Medicare to avoid late enrollment penalties.

Does Medicaid cover Zepbound for obesity? Coverage varies by state. As of April 2026, Louisiana, West Virginia, and Minnesota cover GLP-1 medications for obesity under Medicaid with prior authorization. Most states cover only the diabetes indication. Medicaid copays are typically $0 to $8 per month, far below Medicare specialty copays.

What if my Medicare plan denies my Zepbound prior authorization? You can appeal. First-level appeals are reviewed by the plan within 7 days. If denied again, request an independent review organization (IRO) evaluation. IROs overturn approximately 40% of denials when providers submit additional clinical evidence. Your provider can also try step therapy documentation showing you completed required medication trials.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Data. 2026.
2. Social Security Act, 42 U.S.C. § 1395y(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
3. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. 108-173.
4. Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b).
5. Lilly USA, LLC. Zepbound Prescribing Information. Revised 2024.
6. Lilly USA, LLC. Mounjaro Prescribing Information. Revised 2024.
7. GoodRx Research. Prior Authorization Survey for GLP-1 Medications. 2025.
8. Centers for Medicare & Medicaid Services. Medicare Enrollment Dashboard. 2025.
9. Kaiser Family Foundation. Medicaid Coverage of GLP-1 Receptor Agonists for Obesity. 2026.
10. Treat and Reduce Obesity Act, H.R. 1577 / S. 596, 118th Congress. 2023-2024.
11. Centers for Medicare & Medicaid Services. Part D Coverage Gap (Donut Hole) Thresholds. 2026.
12. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2026.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
14. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.